The ADDoPT consortium partners have met for a project kick-off meeting at the West London headquarters of project coordinator Process Systems Enterprise Limited. The meeting represented an early opportunity for the partners to define responsibilities and establish links across the consortium, and to start fleshing out the various workstreams in the 4 year £20.4m collaborative project, which has been established with the aim of transforming the UK pharmaceutical industry by enabling the manufacturing processes of the innovative medicines of the future to be designed digitally.
ADDoPT (Advanced Digital Design of Pharmaceutical Therapeutics) addresses a key challenge for the pharmaceutical industry; getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure access for patients. The collaboration is pursuing this goal by developing and implementing advanced digital design techniques that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.
‘Digital design’ combines research insight and mechanistic modelling to provide links between raw materials, formulation, manufacturing processes and drug product quality. It spans all operations, processes and procedures during the development and manufacture of medicines, and their in vivo application.
ADDoPT is a four-year collaboration between government, industry and academia. Led by Process Systems Enterprise and supported by the Medicines Manufacturing Industry Partnership (MMIP), it involves pharmaceutical companies Pfizer, GlaxoSmithKline, AstraZeneca and Bristol-Myers Squibb, as well as leading UK universities, research centres, and knowledge-driven technology SMEs. It was initiated by the Medicines Manufacturing Industry Partnership, and is receiving financial support under the Advanced Manufacturing Supply Chain Initiative (AMSCI).
15th January 2016